BACKGROUND Cangrelor, an intravenous, rapidly acting P2Y12 inhibitor, is superior to clopidogrel in reducing ischemic events in PCI patients with stable ischemic heart disease and acute coronary syndromes. We examined the safety and efficacy of cangrelor in relation to the extent of coronary artery disease.
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METHODS
We studied a prespecified modified intention to treat population of patients with single vessel and multivessel coronary disease. The primary efficacy outcome was the composite of death, myocardial infarction (MI), ischemia-driven revascularization (IDR), and stent thrombosis (ST) at 48 hours. Kaplan Meier analysis of the primary outcome was performed through 30 days. The safety outcome was non-CABG GUSTO severe bleeding at 48 hours.
RESULTS Among 10,921 patients, 5,296 (48%) had single vessel disease (SVD) and 5,625 (52%) had multivessel disease (MVD). Patients with MVD were older (65 vs. 63 years), less often female (25% vs. 31%), and more often had diabetes (31% vs. 25%), hypertension (82% vs. 77%), and prior MI (25% vs. 16%). At 48 hours, MVD patients had higher rates of death/MI/IDR/ST (6.3% v 4.2%, p¼<0.001), but not GUSTO severe bleeding (0.1% vs. 0.2%, p¼0.71) compared with SVD patients. Consistent with outcomes in the overall population, cangrelor resulted in fewer death/MI/IDR/ST events compared with clopidogrel in patients with SVD (3.9% v 4.5%; OR 0.88 BACKGROUND Optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for complex coronary lesions and patients is still controversial. There is no randomized study investigating shorter (6 months) vs. standard (12 months) duration of DAPT after PCI for bifurcation lesions. We sought to report the 18-month results of the bifurcation substudy from the I-LOVE-IT 2 trial, which compared safety and efficacy between patients receiving 6-vs. 12-month DAPT after implantation of a novel biodegradable polymer sirolimus-eluting stent (BP-SES).
In the prospective randomized I-LOVE-IT 2 trial, 1829 patients who were allocated to the BP-SES group were also randomized to receive either 6-month (n¼909) or 12-month DAPT (n¼920) pre-stenting; among them there were 717 patients (349 in 6-month DAPT group and 368 in 12-month DAPT group, respectively) with bifurcation lesions. The major endpoints were target lesion failure (TLF, a RESULTS The demographic, lesion or procedural characteristics were similar between groups. Eighteen-month TLF rate was numerically higher in the 6-month DAPT group compared to the 12-month DAPT group (9.3% vs. 5.5%, p¼0.055), which was mainly driven by an increased CI-TLR between 6 and 18 months (3.5% vs. 1.1%, p¼0.03) in the 6-month DAPT group when patients have discontinued DAPT. There were no significant differences in NACCE, death, MI, stroke, and stent thrombosis (ST) at 18 months or between 6 and 18 months period of follow-up. However, there was a non-significant tendency of lower all bleeding events in favoring 6-month DAPT strategy according to the landmark analysis (1.2% vs. 3.3%, p¼0.056). Major clinical outcomes were shown in table. BACKGROUND Patients with coronary artery disease who undergo stent implantation and have concomitant indication for long term oral anticoagulation represent a considerable percentage of the overall population. To date there is still no consensus about the optimal antithrombotic strategy to choose in this kind of patients, due to the difficult balance between an increased risk of bleeding and thromboembolic complications. Aim of this meta-analysis was to evaluate risk and benefits of triple antihrombotic therapy versus dual antiplatelet therapy in patients undergoing coronary stent implantation, requiring long term oral anticoagulation.
We performed formal searches of PubMed, EMBASE, Cochrane central register of controlled trials and major international scientific session abstracts from January 1990 to September 2014 regarding the use of triple antithrombotic therapy versus dual antithrombotic therapy in patients undergoing percutaneous coronary stent implantation that required chronic oral anticoagulation. Data regarding study design, inclusion/exclusion criteria, number of patients, and selected endpoints was extracted by 2 investigators. Disagreements were resolved by consensus.
RESULTS Twelve trials, with a total of 7838 patients undergoing stent implantation with indication to long term oral anticoagulation were finally included. A total of 2686 patients were treated with triple therapy whereas 5152 patients received dual antithrombotic therapy alone. CONCLUSIONS This meta-analysis showed that among patients undergoing coronary stent implantation, requiring chronic oral anticoagulation, the use of a triple antithrombotic therapy is associated with a significant reduction in mortality that largely outweighed the higher risk of major bleeding complications associated with triple therapy. 
